MK-0159 is an orally active, potent and selective CD38 inhibitor (h/m/r CD38 IC50 = 22/3/70 nM) that increases extra- and intracellular NAD+ levels in high CD38-expressing human epithelial A549 cultures, as well as intracellular NAD+/NADP+ in HMVECs (0.3-50 µM). MK-0159 (3-30 mg/kg p.o.) increases systemic NAD+ and decreases ADPR levels in mice, providing protection from myocardial damage upon cardiac I/R injury in vivo (30 mg/kg p.o.).
Potent and selective CD38 inhibitor that protects mice from myocardial damage upon cardiac I/R injury in vivo.
Journal of medicinal chemistry, 65(13), 9418-9446 (2022-06-29)
CD38 is one of the major nicotinamide adenine dinucleotide (NAD+)- and nicotinamide adenine dinucleotide phosphate (NADP+)-consuming enzymes in mammals. NAD+, NADP+, and their reduced counterparts are essential coenzymes for numerous enzymatic reactions, including the maintenance of cellular and mitochondrial redox
Infection is one of the major causes of mortality in patients with systemic lupus erythematosus (SLE). We previously found that CD38, an ectoenzyme that regulates the production of NAD+, is up-regulated in CD8+ T cells of SLE patients and correlates
